List of Studies ( Metabolite:8S,15S-DiHETE)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004138 | AN006861 | Variation in microbiome and metabolites are associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus | Feces | Human | Autoimmune disease | Hangzhou Xixi Hospital | LC-MS |
| ST004138 | AN006861 | Variation in microbiome and metabolites are associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus | Feces | Human | Liver disease | Hangzhou Xixi Hospital | LC-MS |
| ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | LC-MS |
| ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | LC-MS |
| ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | LC-MS |
| ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | LC-MS |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
